Posts by Peter W. PENG

In recent years, the emergence and breakthrough progress of multiple targeted and immunotherapy drugs, along with their combination regimens, have brought significant transformation to the systemic treatment of esophageal and gastric cancer. The field has evolved from monotherapy with targeted or immune agents to an era of dual or multi-immunotherapy combinations.

For patients with recurrent metastatic triple-negative breast cancer (TNBC), would you choose "chemotherapy + immunotherapy" or "ADC" for treatment? At the 2024 Breast Cancer Summer Forum·Northern Salon "In-Depth Analysis" session, Dr. Wei Li from Jiangsu Provincial People's Hospital and Dr. Shaohua Zhang from the Chinese PLA General Hospital presented their respective viewpoints. Dr. Wei Li expressed a preference for "chemotherapy + immunotherapy," while Dr. Shaohua Zhang opted for "ADC." Following the session, Oncology Frontier invited the two experts to elaborate on their perspectives.

At the San Antonio Breast Cancer Symposium (SABCS) 2024, Joyce O’Shaughnessy presented findings from the KEYNOTE-522 trial, a phase 3 study evaluating pembrolizumab in combination with chemotherapy for early-stage triple-negative…

The 2024 World Conference on Lung Cancer is taking place in San Diego from September 7th to 10th! Some key abstracts have already been released. Here’s an overview of the…

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) took place from January 23 to 25 in San Francisco, bringing together the latest advancements in digestive tract oncology. Paclitaxel remains one of the most important chemotherapeutic agents for gastric cancer treatment. However, the traditional intravenous (IV) formulation has long been associated with significant adverse effects. Chinese researchers have continued to optimize the structure and formulation of paclitaxel, aiming for better efficacy and safety, ultimately leading to the successful development and approval of the world's first oral paclitaxel solution.

Healthy living for all, together we uphold, and start a new chapter! September is the National Healthy Lifestyle Promotion Month. We focus on breast cancer, a significant disease threatening women's health, and have specially invited authoritative experts in the field of breast cancer from China to discuss the scientific prevention and treatment of breast cancer and the importance of a healthy lifestyle. The experts unanimously emphasize that facing the disease scientifically, actively preventing it, and treating it precisely are the keys to overcoming breast cancer. Let us join hands with a scientific attitude and firm belief to protect the beauty and dignity of life, and promote breast cancer prevention and treatment to new heights, contributing to the great goal of a Healthy China! We hope that through the experts' interpretations, we can not only enhance the public's understanding of breast cancer but also encourage patients and their families to actively participate in screening and advocate a healthy lifestyle, jointly promoting the development of breast cancer treatment towards more individualized and precise directions. Let us work together to light the way for breast cancer patients and create a healthy and bright future!